Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lifestream cholesterol test

This article was originally published in The Tan Sheet

Executive Summary

Lifestream Technologies receives FDA 510k clearance to market consumer cholesterol test incorporating Health Risk Assessment technology, enabling users to track cholesterol levels as well as personal risk of heart attack and obesity. Users can obtain a Health Risk Assessment profile after taking a three-minute cholesterol test and entering additional risk factors, including diabetic status, systolic and diastolic blood pressure and HDL-C break-out from a recent lipid profile. The test will be available to consumers through the firm's 1website in late June and move to other distribution channels later this year. McNeil recently announced a licensing agreement with International Medical Innovations to develop and market the PREVU(x) consumer cholesterol test (2"The Tan Sheet" June 7, 2004, p. 10)...

You may also be interested in...



McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI

McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)

Bayer Confident CureVac COVID Pact Will Be A Success

CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.

EMA Works On Defining Metadata From RWD Sources

As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel